Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

Stock Information for Allakos Inc.

Loading

Please wait while we load your information from QuoteMedia.